PMID- 35641932
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220716
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 31
TI  - Correlation between the thyroid hormone levels and nonalcoholic fatty liver 
      disease in type 2 diabetic patients with normal thyroid function.
PG  - 144
LID - 10.1186/s12902-022-01050-2 [doi]
LID - 144
AB  - BACKGROUND: The objective of this study is to retrospectively analyze the 
      correlation between the thyroid hormones and nonalcoholic fatty liver disease 
      (NAFLD) in type 2 diabetes mellitus (T2DM) patients with normal thyroid function. 
      METHODS: Totally 586 T2DM patients with normal thyroid function participated in 
      this research and were divided into T2DM without NAFLD (240 cases) group and T2DM 
      with NAFLD (346 cases) group. The NAFLD fibrosis score (NFS) > 0.676 was defined 
      as progressive liver fibrosis and used to categorize the patients into T2DM 
      without progressive liver fibrosis group (493 cases) and T2DM with progressive 
      liver fibrosis group (93 cases). RESULTS: The results indicated that the levels 
      of free triiodothyronine (FT3), total triiodomethylamine (TT3) and FT3/free 
      thyroxine ratio (FT3/FT4) were significantly higher while the FT4 level was lower 
      in T2DM with NAFLD group than that in T2DM without NAFLD group (p < 0.05). The 
      levels of FT3, FT4, TT3 and TT4 in patients with progressive liver fibrosis were 
      significantly lower in patients with progressive liver fibrosis than that in 
      patients without progressive liver fibrosis (p < 0.05). Logistic regression 
      analysis showed a positive connection between FT3/FT4 ratio and NAFLD 
      (p = 0.038), a negative relationship between FT4 level and NAFLD (p = 0.026), 
      between the levels of FT4, TT3 and total thyroxine (TT4) and the risk of 
      progressive hepatic fibrosis (p = 0.022, p = 0.007, p = 0.046). CONCLUSION: There 
      is a certain correlation between thyroid hormone levels and NAFLD in T2DM 
      patients, suggesting that the assessment of thyroid hormone levels in T2DM 
      patients with normal thyroid function could be helpful in the prevention and 
      treatment of NAFLD.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Li, Juyi
AU  - Li J
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Liu, Huaizhen
AU  - Liu H
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China. 
      1140808869@qq.com.
LA  - eng
GR  - 2020yfyzc22/Anhui University of Traditional Chinese Medicine/
GR  - 2020yfyzc22/Anhui University of Traditional Chinese Medicine/
GR  - 2020yfyzc22/Anhui University of Traditional Chinese Medicine/
PT  - Journal Article
DEP - 20220531
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Thyroid Hormones)
RN  - Q51BO43MG4 (Thyroxine)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - Liver Cirrhosis/diagnosis/etiology
MH  - *Non-alcoholic Fatty Liver Disease/complications
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thyroid Gland
MH  - Thyroid Hormones
MH  - Thyroxine
PMC - PMC9158236
OTO - NOTNLM
OT  - Nonalcoholic fatty liver disease
OT  - Progressive liver fibrosis
OT  - Thyroid hormones
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2022/06/02 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/05/31
CRDT- 2022/06/01 00:15
PHST- 2021/07/28 00:00 [received]
PHST- 2022/03/25 00:00 [accepted]
PHST- 2022/06/01 00:15 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/05/31 00:00 [pmc-release]
AID - 10.1186/s12902-022-01050-2 [pii]
AID - 1050 [pii]
AID - 10.1186/s12902-022-01050-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 May 31;22(1):144. doi: 10.1186/s12902-022-01050-2.